People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arbor Biotechnologies, Inc. | — | Biotechnology | Series D+ | $230.6M | $5.7B | 2017 |
KEITH XIA CRANDELL at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KEITH XIA CRANDELL on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Murphy | 1 | 17 |
| Paul Meister | 1 | 12 |
| Keith Crandell | 1 | 11 |
| Chen Yu | 1 | 7 |
| David Walt | 1 | 6 |
| David R. Walt | 1 | 5 |
| Mark Angelino | 1 | 4 |
| David Cheng | 1 | 3 |
| Kelly Morgan | 1 | 2 |
| RAMI HARAWI | 1 | 1 |
| PAM STETKIEWICZ | 1 | 1 |
| DEVYN SMITH | 1 | 1 |
| DAVID ARTHUR SCOTT | 1 | 1 |
| WINSTON XIA YAN | 1 | 1 |
| ANNIE XIA HAZLEHURST | 1 | 1 |
| FENG R. ZHANG | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.